Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.13 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items.
A quarter ago, it was expected that this company would post a loss of $0.09 per share when it actually produced a loss of $0.07, delivering a surprise of 22.22%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.